PortalPublikationenEffects of the COVID-19 Pandemic on Patients With NMO Spectr...

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study

Standard

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study. / Hümmert, Martin W; Bütow, Franziska; Tkachenko, Daria; Ayzenberg, Ilya; Pakeerathan, Thivya; Hellwig, Kerstin; Klotz, Luisa; Häußler, Vivien; Stellmann, Jan-Patrick; Warnke, Clemens; Goereci, Yasemin; Etgen, Thorleif; Luessi, Felix; Bronzlik, Paul; Gingele, Stefan; Lauenstein, Ann-Sophie; Kleiter, Ingo; Rommer, Paulus S; Paul, Friedemann; Bellmann-Strobl, Judith; Duchow, Ankelien; Then Bergh, Florian; Pul, Refik; Walter, Annette; Pellkofer, Hannah; Kümpfel, Tania; Pompsch, Mosche; Kraemer, Markus; Albrecht, Philipp; Aktas, Orhan; Ringelstein, Marius; Senel, Makbule; Giglhuber, Katrin; Berthele, Achim; Jarius, Sven; Wildemann, Brigitte; Trebst, Corinna; Neuromyelitis Optica Study Group (NEMOS).

in: NEUROL-NEUROIMMUNOL, Jahrgang 10, Nr. 2, e200082, 03.2023.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hümmert, MW, Bütow, F, Tkachenko, D, Ayzenberg, I, Pakeerathan, T, Hellwig, K, Klotz, L, Häußler, V, Stellmann, J-P, Warnke, C, Goereci, Y, Etgen, T, Luessi, F, Bronzlik, P, Gingele, S, Lauenstein, A-S, Kleiter, I, Rommer, PS, Paul, F, Bellmann-Strobl, J, Duchow, A, Then Bergh, F, Pul, R, Walter, A, Pellkofer, H, Kümpfel, T, Pompsch, M, Kraemer, M, Albrecht, P, Aktas, O, Ringelstein, M, Senel, M, Giglhuber, K, Berthele, A, Jarius, S, Wildemann, B, Trebst, C & Neuromyelitis Optica Study Group (NEMOS) 2023, 'Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study', NEUROL-NEUROIMMUNOL, Jg. 10, Nr. 2, e200082. https://doi.org/10.1212/NXI.0000000000200082

APA

Hümmert, M. W., Bütow, F., Tkachenko, D., Ayzenberg, I., Pakeerathan, T., Hellwig, K., Klotz, L., Häußler, V., Stellmann, J-P., Warnke, C., Goereci, Y., Etgen, T., Luessi, F., Bronzlik, P., Gingele, S., Lauenstein, A-S., Kleiter, I., Rommer, P. S., Paul, F., ... Neuromyelitis Optica Study Group (NEMOS) (2023). Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study. NEUROL-NEUROIMMUNOL, 10(2), [e200082]. https://doi.org/10.1212/NXI.0000000000200082

Vancouver

Hümmert MW, Bütow F, Tkachenko D, Ayzenberg I, Pakeerathan T, Hellwig K et al. Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study. NEUROL-NEUROIMMUNOL. 2023 Mär;10(2). e200082. https://doi.org/10.1212/NXI.0000000000200082

Bibtex

@article{0061fa9387c34ee48e59638a4f8d4579,
title = "Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study",
abstract = "BACKGROUND AND OBJECTIVES: To evaluate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the life of patients with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated diseases (MOGAD).METHODS: This multicenter, cross-sectional study included data of 187 patients recruited from 19 different German and Austrian Neuromyelitis Optica Study Group (NEMOS) centers between July 2021 and March 2022. The effects of the pandemic on immunotherapeutic treatment and access to care, the possible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential effect of vaccination against SARS-CoV-2 on disease incidence and relapse risk were assessed using a patient questionnaire. Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clinical characteristics were retrieved from the NEMOS database.RESULTS: One hundred eighty-seven patients (75% women; median age 47 [range 21-86] years; median disease duration 5.5 [range 0-67] years; median Expanded Disability Status Scale 2.0 [range 0-8.0]; 51% aquaporin-4 immunoglobulin G (AQP4-IgG)-positive, 36% myelin oligodendrocyte glycoprotein (MOG)-IgG-positive 13% double-seronegative) were analyzed. Most patients maintained excellent access to healthcare services throughout the pandemic. Immunotherapy was not changed in 88% of patients. Ninety-one percent of all patients were satisfied with medical care during the pandemic. Nearly two-thirds (64%) of patients rated their risk of infection with SARS-CoV-2 as low or moderate. Among this study sample, 23 patients (12%) knowingly acquired an infection with SARS-CoV-2 and predominantly had a nonsevere course of illness (n = 22/23, 96%). The SARS-CoV-2 vaccination rate was 89%, with 4 cases of confirmed attack or first manifestation of NMOSD/MOGAD occurring in temporal association with the vaccination (range 2-9 days). The reported HRQoL did not decline compared with a prepandemic assessment (mean EQ-5D-5L index value 0.76, 95% bootstrap confidence interval [CI] 0.72-0.80; mean EQ-VAS 66.5, 95% bootstrap CI 63.5-69.3).DISCUSSION: This study demonstrates that, overall, patients with NMOSD/MOGAD affiliated with specialized centers received ongoing medical care during the pandemic. Patients' satisfaction with medical care and HRQoL did not decrease.",
keywords = "Humans, Female, Male, Neuromyelitis Optica/epidemiology, Pandemics, Myelin-Oligodendrocyte Glycoprotein, Cross-Sectional Studies, COVID-19 Vaccines, Quality of Life, COVID-19/epidemiology, SARS-CoV-2, Immunoglobulin G",
author = "H{\"u}mmert, {Martin W} and Franziska B{\"u}tow and Daria Tkachenko and Ilya Ayzenberg and Thivya Pakeerathan and Kerstin Hellwig and Luisa Klotz and Vivien H{\"a}u{\ss}ler and Jan-Patrick Stellmann and Clemens Warnke and Yasemin Goereci and Thorleif Etgen and Felix Luessi and Paul Bronzlik and Stefan Gingele and Ann-Sophie Lauenstein and Ingo Kleiter and Rommer, {Paulus S} and Friedemann Paul and Judith Bellmann-Strobl and Ankelien Duchow and {Then Bergh}, Florian and Refik Pul and Annette Walter and Hannah Pellkofer and Tania K{\"u}mpfel and Mosche Pompsch and Markus Kraemer and Philipp Albrecht and Orhan Aktas and Marius Ringelstein and Makbule Senel and Katrin Giglhuber and Achim Berthele and Sven Jarius and Brigitte Wildemann and Corinna Trebst and {Neuromyelitis Optica Study Group (NEMOS)}",
note = "Copyright {\textcopyright} 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.",
year = "2023",
month = mar,
doi = "10.1212/NXI.0000000000200082",
language = "English",
volume = "10",
journal = "NEUROL-NEUROIMMUNOL",
issn = "2332-7812",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

RIS

TY - JOUR

T1 - Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study

AU - Hümmert, Martin W

AU - Bütow, Franziska

AU - Tkachenko, Daria

AU - Ayzenberg, Ilya

AU - Pakeerathan, Thivya

AU - Hellwig, Kerstin

AU - Klotz, Luisa

AU - Häußler, Vivien

AU - Stellmann, Jan-Patrick

AU - Warnke, Clemens

AU - Goereci, Yasemin

AU - Etgen, Thorleif

AU - Luessi, Felix

AU - Bronzlik, Paul

AU - Gingele, Stefan

AU - Lauenstein, Ann-Sophie

AU - Kleiter, Ingo

AU - Rommer, Paulus S

AU - Paul, Friedemann

AU - Bellmann-Strobl, Judith

AU - Duchow, Ankelien

AU - Then Bergh, Florian

AU - Pul, Refik

AU - Walter, Annette

AU - Pellkofer, Hannah

AU - Kümpfel, Tania

AU - Pompsch, Mosche

AU - Kraemer, Markus

AU - Albrecht, Philipp

AU - Aktas, Orhan

AU - Ringelstein, Marius

AU - Senel, Makbule

AU - Giglhuber, Katrin

AU - Berthele, Achim

AU - Jarius, Sven

AU - Wildemann, Brigitte

AU - Trebst, Corinna

AU - Neuromyelitis Optica Study Group (NEMOS)

N1 - Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

PY - 2023/3

Y1 - 2023/3

N2 - BACKGROUND AND OBJECTIVES: To evaluate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the life of patients with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated diseases (MOGAD).METHODS: This multicenter, cross-sectional study included data of 187 patients recruited from 19 different German and Austrian Neuromyelitis Optica Study Group (NEMOS) centers between July 2021 and March 2022. The effects of the pandemic on immunotherapeutic treatment and access to care, the possible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential effect of vaccination against SARS-CoV-2 on disease incidence and relapse risk were assessed using a patient questionnaire. Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clinical characteristics were retrieved from the NEMOS database.RESULTS: One hundred eighty-seven patients (75% women; median age 47 [range 21-86] years; median disease duration 5.5 [range 0-67] years; median Expanded Disability Status Scale 2.0 [range 0-8.0]; 51% aquaporin-4 immunoglobulin G (AQP4-IgG)-positive, 36% myelin oligodendrocyte glycoprotein (MOG)-IgG-positive 13% double-seronegative) were analyzed. Most patients maintained excellent access to healthcare services throughout the pandemic. Immunotherapy was not changed in 88% of patients. Ninety-one percent of all patients were satisfied with medical care during the pandemic. Nearly two-thirds (64%) of patients rated their risk of infection with SARS-CoV-2 as low or moderate. Among this study sample, 23 patients (12%) knowingly acquired an infection with SARS-CoV-2 and predominantly had a nonsevere course of illness (n = 22/23, 96%). The SARS-CoV-2 vaccination rate was 89%, with 4 cases of confirmed attack or first manifestation of NMOSD/MOGAD occurring in temporal association with the vaccination (range 2-9 days). The reported HRQoL did not decline compared with a prepandemic assessment (mean EQ-5D-5L index value 0.76, 95% bootstrap confidence interval [CI] 0.72-0.80; mean EQ-VAS 66.5, 95% bootstrap CI 63.5-69.3).DISCUSSION: This study demonstrates that, overall, patients with NMOSD/MOGAD affiliated with specialized centers received ongoing medical care during the pandemic. Patients' satisfaction with medical care and HRQoL did not decrease.

AB - BACKGROUND AND OBJECTIVES: To evaluate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the life of patients with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated diseases (MOGAD).METHODS: This multicenter, cross-sectional study included data of 187 patients recruited from 19 different German and Austrian Neuromyelitis Optica Study Group (NEMOS) centers between July 2021 and March 2022. The effects of the pandemic on immunotherapeutic treatment and access to care, the possible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential effect of vaccination against SARS-CoV-2 on disease incidence and relapse risk were assessed using a patient questionnaire. Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clinical characteristics were retrieved from the NEMOS database.RESULTS: One hundred eighty-seven patients (75% women; median age 47 [range 21-86] years; median disease duration 5.5 [range 0-67] years; median Expanded Disability Status Scale 2.0 [range 0-8.0]; 51% aquaporin-4 immunoglobulin G (AQP4-IgG)-positive, 36% myelin oligodendrocyte glycoprotein (MOG)-IgG-positive 13% double-seronegative) were analyzed. Most patients maintained excellent access to healthcare services throughout the pandemic. Immunotherapy was not changed in 88% of patients. Ninety-one percent of all patients were satisfied with medical care during the pandemic. Nearly two-thirds (64%) of patients rated their risk of infection with SARS-CoV-2 as low or moderate. Among this study sample, 23 patients (12%) knowingly acquired an infection with SARS-CoV-2 and predominantly had a nonsevere course of illness (n = 22/23, 96%). The SARS-CoV-2 vaccination rate was 89%, with 4 cases of confirmed attack or first manifestation of NMOSD/MOGAD occurring in temporal association with the vaccination (range 2-9 days). The reported HRQoL did not decline compared with a prepandemic assessment (mean EQ-5D-5L index value 0.76, 95% bootstrap confidence interval [CI] 0.72-0.80; mean EQ-VAS 66.5, 95% bootstrap CI 63.5-69.3).DISCUSSION: This study demonstrates that, overall, patients with NMOSD/MOGAD affiliated with specialized centers received ongoing medical care during the pandemic. Patients' satisfaction with medical care and HRQoL did not decrease.

KW - Humans

KW - Female

KW - Male

KW - Neuromyelitis Optica/epidemiology

KW - Pandemics

KW - Myelin-Oligodendrocyte Glycoprotein

KW - Cross-Sectional Studies

KW - COVID-19 Vaccines

KW - Quality of Life

KW - COVID-19/epidemiology

KW - SARS-CoV-2

KW - Immunoglobulin G

U2 - 10.1212/NXI.0000000000200082

DO - 10.1212/NXI.0000000000200082

M3 - SCORING: Journal article

C2 - 36693760

VL - 10

JO - NEUROL-NEUROIMMUNOL

JF - NEUROL-NEUROIMMUNOL

SN - 2332-7812

IS - 2

M1 - e200082

ER -